Lubeluzole pharmacokinetics in subjects with mild, moderate and severe renal impairment.

被引：0
|
作者：
Burstein, AH
Lee, PID
Gajjar, D
Zhou, H
Soo, Y
Pesco-Koplowitz, L
Hantson, L
Woestenborghs, R
Young, D
机构：
[1] GloboMax LLC, Hanover, MD USA
[2] Janssen Res Fdn, Titusville, NJ USA
[3] Univ Maryland, Sch Pharm, Baltimore, MD 21201 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 1998年 / 63卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII68
引用
收藏
页码：189 / 189
页数：1
相关论文
共 50 条
  • [1] THE PHARMACOKINETICS AND SAFETY OF MOMELOTINIB IN SUBJECTS WITH MODERATE OR SEVERE RENAL IMPAIRMENT.
    Xin, Y.
    Collins, H.
    Cheng, F.
    Kwan, E.
    Ramanathan, S.
    Silverman, J. A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S87 - S88
  • [2] PHARMACOKINETICS (PK) OF FENOFIBRIC ACID AND ROSUVASTATIN IN SUBJECTS WITH MILD TO MODERATE RENAL IMPAIRMENT.
    Zhu, T.
    Williams, L.
    Awni, W.
    Smith, W.
    Locke, C.
    Pradhan, R.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 : S27 - S27
  • [3] The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment.
    Jin, Feng
    Robeson, Michelle
    Zhou, Huafeng
    Hisoire, Grace
    Ramanathan, Srini
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] THE PHARMACOKINETICS AND SAFETY OF MOMELOTINIB IN SUBJECTS WITH MODERATE OR SEVERE HEPATIC IMPAIRMENT.
    Xin, Y.
    Collins, H.
    Cheng, F.
    Kwan, E.
    Ramanathan, S.
    Silverman, J. A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S88 - S88
  • [5] Pharmacokinetics of sugammadex in subjects with moderate and severe renal impairment
    Min, K. Chris
    Lasseter, Kenneth C.
    Marbury, Thomas C.
    Wrishko, Rebecca E.
    Hanley, William D.
    Wolford, Dennis G.
    de Haes, Joanna Udo
    Reitmann, Christina
    Gutstein, David E.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2017, 55 (09) : 746 - 752
  • [6] The pharmacokinetics of dalbavancin in subjects with mild, moderate, or severe hepatic impairment
    J Dowell
    E Seltzer
    M Buckwalter
    T Marbury
    D Simoneau
    E Boudry
    [J]. Critical Care, 12 (Suppl 2):
  • [7] Pharmacokinetics of benapenem for injection in subjects with mild to moderate renal impairment
    Yang, Haijing
    Zhang, Min
    Chen, Yuancheng
    Ren, Hong
    Zhang, Hong
    Yu, Chen
    Lu, Jianda
    You, Li
    Yu, Jicheng
    Liang, Hong
    Xiao, Cuilan
    He, Zishuang
    Wu, Jufang
    Xue, Jun
    Zhang, Jing
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (07) : 1079 - 1086
  • [8] Pharmacokinetics of benapenem for injection in subjects with mild to moderate renal impairment
    Haijing Yang
    Min Zhang
    Yuancheng Chen
    Hong Ren
    Hong Zhang
    Chen Yu
    Jianda Lu
    Li You
    Jicheng Yu
    Hong Liang
    Cuilan Xiao
    Zishuang He
    Jufang Wu
    Jun Xue
    Jing Zhang
    [J]. European Journal of Clinical Pharmacology, 2022, 78 : 1079 - 1086
  • [9] FTY720 pharmacokinetics in mild to moderate hepatic impairment.
    Kovarik, JM
    Schmouder, RL
    Serra, D
    Wang, Y
    Lasseter, K
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 473 - 473
  • [10] Pharmacokinetics of insulin detemir in subjects with renal or hepatic impairment.
    Jacobsen, LV
    Popescu, G
    Plum, A
    [J]. DIABETOLOGIA, 2002, 45 : A259 - A260
12345